Boehringer offers selected pre-clinical molecules to scientists worldwide for free via new platform

Boehringer Ingelheim has recently unveiled, a centralised platform that allows access to selected pre-clinical molecules from its portfolio for free for non-clinical investigation by international scientists. The German pharmaceutical company hopes that the move will stimulate independent drug discovery and collaborative partnerships worldwide, in addition to the identification of novel treatment solutions for patients.

Continue Reading